Fifth Third Bancorp raised its position in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 912.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,971 shares of the company’s stock after purchasing an additional 19,801 shares during the period. Fifth Third Bancorp’s holdings in Henry Schein were worth $1,619,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Assenagon Asset Management S.A. increased its stake in Henry Schein by 212.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 67,181 shares of the company’s stock valued at $5,078,000 after purchasing an additional 45,701 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Henry Schein during the 3rd quarter worth approximately $15,375,000. Heartland Advisors Inc. acquired a new position in shares of Henry Schein in the 4th quarter valued at $9,070,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Henry Schein by 15.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 115,279 shares of the company’s stock valued at $8,856,000 after buying an additional 15,765 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Henry Schein by 10,448.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 42,193 shares of the company’s stock worth $3,189,000 after acquiring an additional 41,793 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.
Henry Schein Trading Down 0.3%
NASDAQ HSIC opened at $84.53 on Friday. The firm’s fifty day moving average is $80.72 and its two-hundred day moving average is $77.99. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.34. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The firm has a market cap of $9.63 billion, a PE ratio of 25.54, a P/E/G ratio of 1.63 and a beta of 0.81.
Analysts Set New Price Targets
Several equities analysts have issued reports on the stock. Citigroup began coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective for the company. Wall Street Zen cut Henry Schein from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Morgan Stanley reissued an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. Finally, BMO Capital Markets began coverage on Henry Schein in a research note on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $87.64.
Get Our Latest Stock Report on Henry Schein
Insiders Place Their Bets
In related news, Director William K. Daniel acquired 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.89% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Featured Stories
- Five stocks we like better than Henry Schein
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
